Phase II study of high‐dose tamoxifen (NSC‐180973) in patients with disseminated malignant melanoma

Edward T. Creagan; James N. Ingle; David L. Ahmann; Stephanie J. Green

doi:10.1002/1097-0142(19820401)49:7<1353::AID-CNCR2820490707>3.0.CO;2-4

Phase II study of high‐dose tamoxifen (NSC‐180973) in patients with disseminated malignant melanoma

Edward T. Creagan, James N. Ingle, David L. Ahmann, Stephanie J. Green

Medical Oncology

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m^2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.

Original language	English (US)
Pages (from-to)	1353-1354
Number of pages	2
Journal	Cancer
Volume	49
Issue number	7
DOIs	https://doi.org/10.1002/1097-0142(19820401)49:7<1353::AID-CNCR2820490707>3.0.CO;2-4
State	Published - Apr 1 1982

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19820401)49:7<1353::AID-CNCR2820490707>3.0.CO;2-4

Cite this

@article{c9a3e30f60354269b1fd04a36ba965fc,

title = "Phase II study of high‐dose tamoxifen (NSC‐180973) in patients with disseminated malignant melanoma",

abstract = "Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.",

author = "Creagan, {Edward T.} and Ingle, {James N.} and Ahmann, {David L.} and Green, {Stephanie J.}",

year = "1982",

month = apr,

day = "1",

doi = "10.1002/1097-0142(19820401)49:7<1353::AID-CNCR2820490707>3.0.CO;2-4",

language = "English (US)",

volume = "49",

pages = "1353--1354",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "7",

}

TY - JOUR

T1 - Phase II study of high‐dose tamoxifen (NSC‐180973) in patients with disseminated malignant melanoma

AU - Creagan, Edward T.

AU - Ingle, James N.

AU - Ahmann, David L.

AU - Green, Stephanie J.

PY - 1982/4/1

Y1 - 1982/4/1

N2 - Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.

AB - Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.

UR - http://www.scopus.com/inward/record.url?scp=0020060187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020060187&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19820401)49:7<1353::AID-CNCR2820490707>3.0.CO;2-4

DO - 10.1002/1097-0142(19820401)49:7<1353::AID-CNCR2820490707>3.0.CO;2-4

M3 - Article

C2 - 7059950

AN - SCOPUS:0020060187

SN - 0008-543X

VL - 49

SP - 1353

EP - 1354

JO - Cancer

JF - Cancer

IS - 7

ER -

Phase II study of high‐dose tamoxifen (NSC‐180973) in patients with disseminated malignant melanoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this